<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428517</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ALLO-044</org_study_id>
    <nct_id>NCT02428517</nct_id>
  </id_info>
  <brief_title>Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)</brief_title>
  <acronym>ATLAS2015</acronym>
  <official_title>A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective multicenter observational study to evaluate the feasibility and
      the efficacy of the conditioning regimens which are modified by the donor differences and the
      age of recipients among patients who will receive allogeneic hematopoietic stem cell
      transplantation in their 1st or 2nd hematologic complete remission (CR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic cell transplantation (AlloHCT) is recommended as a post-remission
      therapy for patients with adult ALL, and reduced intensity conditioning has been tried to
      decrease treatment-related mortality (TRM) rate.

      Recent results showed that reduced intensity conditioning can be safely and effectively used
      for alloHCT of adult patients with ALL. However, the reduced intensity conditioning (RIC) can
      increase the possibilities of hematologic relapse, especially due to the reduced
      anti-leukemic effect. Another challenge in performing alloHCT for ALL is the donor
      availability - the limited availability of matched sibling donor (MSD) and well-matched
      unrelated donor (WMUD) forces us to find the feasibility of alternative donors such as
      partially-matched unrelated donor (PMUD) or haploidentical familial donor (familial
      mismatched donor, FMD).

      The previous study (NCT0137764) which the investigators performed showed that the use of RIC
      and alternative donor was feasible. However, the incidence of relapse was slightly higher
      among patients who received RIC when the investigators analyzed the interim analysis results.
      Especially, the graft-versus-host disease (GVHD) incidence was relatively higher among
      patients who received alloHCT from MSD, and the investigators think that the addition of
      antithymocyte globulin will reduce the incidence of GVHD for these patients.

      In this study, the dose of busulfan will be increased when the recipients are below 55 years
      old, irrespective of donor type. The investigators will also define the partially matched
      donor exactly and find the feasibility of PMUD and FMD again. Another endpoint for this study
      is to find out whether the addition of antithymocyte globulin may be helpful in preventing
      the GVHD incidence for patients who received alloHCT from MSD without increasing the chance
      of hematologic relapse.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI resigned the institute, and the rest investigators at the institute decided to terminate
    the study.
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relapse-free survival (RFS) rate</measure>
    <time_frame>2 years</time_frame>
    <description>time from achieving hematologic CR to hematologic relapse / time from the enrollment of this trial to hematologic relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival (RFS) rate</measure>
    <time_frame>5 years</time_frame>
    <description>time from achieving hematologic CR to hematologic relapse / time from the enrollment of this trial to hematologic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS) rate</measure>
    <time_frame>2 years</time_frame>
    <description>time from the diagnosis of disease to death/ time from the enrollment of this trial to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS) rate</measure>
    <time_frame>5 years</time_frame>
    <description>time from the diagnosis of disease to death/ time from the enrollment of this trial to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>2 years</time_frame>
    <description>from achieving hematologic CR to hematologic relapse / time from the enrollment of this trial to hematologic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>5 years</time_frame>
    <description>from achieving hematologic CR to hematologic relapse / time from the enrollment of this trial to hematologic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality rate</measure>
    <time_frame>100 days</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality rate</measure>
    <time_frame>1 year</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality rate</measure>
    <time_frame>2 years</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality rate</measure>
    <time_frame>5 years</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of acute graft-versus-host disease</measure>
    <time_frame>100 days</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of acute graft-versus-host disease</measure>
    <time_frame>1 year</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of acute graft-versus-host disease</measure>
    <time_frame>2 years</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of acute graft-versus-host disease</measure>
    <time_frame>5 years</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of chronic graft-versus-host disease</measure>
    <time_frame>100 days</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of chronic graft-versus-host disease</measure>
    <time_frame>1 year</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of chronic graft-versus-host disease</measure>
    <time_frame>2 years</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of chronic graft-versus-host disease</measure>
    <time_frame>5 years</time_frame>
    <description>after enrollment of this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>after enrollment of this trial / after achieving molecular CR (for Ph-positive ALL)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Precursor Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <arm_group>
    <arm_group_label>Young/MSD</arm_group_label>
    <description>Patients who are &lt;55 years old, and will receive alloHCT for Young/MSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young/MUD&amp;FMD</arm_group_label>
    <description>Patients who are &lt;55 years old, and will receive alloHCT for Young/MUD&amp;FMD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Old/MSD</arm_group_label>
    <description>Patients who are &gt;=55 years old, and will receive alloHCT for Old/MSD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Old/MUD&amp;FMD</arm_group_label>
    <description>Patients who are &gt;=55 years old, and will receive alloHCT for Old/MUD&amp;FMD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AlloHCT for Young/MSD</intervention_name>
    <description>Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)</description>
    <arm_group_label>Young/MSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AlloHCT for Young/MUD&amp;FMD</intervention_name>
    <description>Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)</description>
    <arm_group_label>Young/MUD&amp;FMD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AlloHCT for Old/MSD</intervention_name>
    <description>Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)</description>
    <arm_group_label>Old/MSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AlloHCT for Old/MUD&amp;FMD</intervention_name>
    <description>Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)</description>
    <arm_group_label>Old/MUD&amp;FMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are diagnosed as acute lymphoblastic leukemia, who achieve hematologic
        complete remission for the first time or for the second time after chemotherapy, and who
        wil receive allogeneic hematopoietic cell transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who has been previously diagnosed as one of the following disease;

               -  Acute lymphoblastic leukemia

               -  Biphenotypic acute leukemia with Philadelphia-positive chromosome or gene
                  translocation

          -  Patients whose disease status is one of the following;

               -  First hematologic complete remission (HCR1)

               -  Second hematologic complete remission (HCR2)

          -  15 years of age and over.

          -  With a suitable donor (matched sibling, well-matched unrelated, partially-matched
             unrelated, and haploidentical familial donor)

          -  Adequate cardiac function (EF&gt;45% via cardiac scan or EchoCG)

          -  European Clinical Oncology Group (ECOG) performance status ≥grade 2 or Karnofsky scale
             &gt;60% at the time of screening

          -  All patients give written informed consent according to guidelines at institution's
             committee on human research.

        Exclusion Criteria:

          -  Acute lymphoblastic leukemia L3 type (Burkitt leukemia/lymphoma)

          -  Biphenotypic acute leukemia without BCR-ABL1 translocation

          -  Lymphoblastic lymphoma (bone marrow blast count is below 20% of mononuclear cells of
             bone marrow aspirate)

          -  Patients with psychiatric disorder or mental deficiency severe as to make compliance
             with the treatment unlike, and making informed consent impossible

          -  Nursing women, pregnant women, women of childbearing potential who do not want
             adequate contraception

          -  Male patient who reject the methods of avoiding pregnancy via methods such as
             abstinence, barrier method (condom etc).

          -  Patients with a diagnosis of prior malignancy (including hematologic malignancies such
             as acute leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome, etc)
             unless disease-free for at least 5 years following therapy with curative intent
             (except curatively treated nonmelanoma skin cancer, in situ carcinoma, or cervical
             intraepithelial neoplasia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae-Young Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital, University of Ulsan College of Medicine</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7. Erratum in: CA Cancer J Clin. 2014 Sep-Oct;64(5):364.</citation>
    <PMID>24399786</PMID>
  </reference>
  <reference>
    <citation>Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep. 2014 Feb 27;4:4227. doi: 10.1038/srep04227.</citation>
    <PMID>24572378</PMID>
  </reference>
  <reference>
    <citation>Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013 Feb 14;121(7):1077-82. doi: 10.1182/blood-2012-08-234492. Epub 2012 Dec 14. Review.</citation>
    <PMID>23243288</PMID>
  </reference>
  <reference>
    <citation>Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, Paietta E, Litzow MR, Marks DI, Durrant J, McMillan A, Franklin IM, Luger S, Ciobanu N, Rowe JM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 Feb 15;111(4):1827-33. Epub 2007 Nov 29.</citation>
    <PMID>18048644</PMID>
  </reference>
  <reference>
    <citation>Bray RA, Hurley CK, Kamani NR, Woolfrey A, Müller C, Spellman S, Setterholm M, Confer DL. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):45-53. doi: 10.1016/j.bbmt.2008.06.014. Review.</citation>
    <PMID>18721780</PMID>
  </reference>
  <reference>
    <citation>Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec 15;110(13):4576-83. Epub 2007 Sep 4.</citation>
    <PMID>17785583</PMID>
  </reference>
  <reference>
    <citation>Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58. doi: 10.1016/j.bbmt.2008.04.003.</citation>
    <PMID>18541193</PMID>
  </reference>
  <reference>
    <citation>Petersdorf EW, Anasetti C, Martin PJ, Gooley T, Radich J, Malkki M, Woolfrey A, Smith A, Mickelson E, Hansen JA. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004 Nov 1;104(9):2976-80. Epub 2004 Jul 13.</citation>
    <PMID>15251989</PMID>
  </reference>
  <reference>
    <citation>Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012 Mar 1;119(9):1972-80. doi: 10.1182/blood-2011-11-354563. Epub 2011 Dec 30. Review.</citation>
    <PMID>22210876</PMID>
  </reference>
  <reference>
    <citation>Koh LP, Rizzieri DA, Chao NJ. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Biol Blood Marrow Transplant. 2007 Nov;13(11):1249-67. Review.</citation>
    <PMID>17950913</PMID>
  </reference>
  <reference>
    <citation>Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011 Dec 1;118(23):6006-17. doi: 10.1182/blood-2011-07-338822. Epub 2011 Sep 14. Review.</citation>
    <PMID>21921045</PMID>
  </reference>
  <reference>
    <citation>Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28.</citation>
    <PMID>21715313</PMID>
  </reference>
  <reference>
    <citation>de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 1;104(3):865-72. Epub 2004 Apr 15.</citation>
    <PMID>15090449</PMID>
  </reference>
  <reference>
    <citation>Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander AR, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser AA, Ringden O. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004 Jul 15;22(14):2816-25.</citation>
    <PMID>15254049</PMID>
  </reference>
  <reference>
    <citation>Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socié G, Golmard JL, Jouet JP; French Society of Bone Marrow Transplantation and Cell Therapy. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006 Dec 20;24(36):5695-702. Epub 2006 Nov 20.</citation>
    <PMID>17116940</PMID>
  </reference>
  <reference>
    <citation>Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007 Jul;21(7):1387-94. Epub 2007 Apr 5. Review.</citation>
    <PMID>17410187</PMID>
  </reference>
  <reference>
    <citation>Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socié G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014 Mar;49(3):389-96. doi: 10.1038/bmt.2013.204. Epub 2014 Jan 13.</citation>
    <PMID>24419525</PMID>
  </reference>
  <reference>
    <citation>Dirou S, Malard F, Chambellan A, Chevallier P, Germaud P, Guillaume T, Delaunay J, Moreau P, Delasalle B, Lemarchand P, Mohty M. Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT. Bone Marrow Transplant. 2014 May;49(5):622-7. doi: 10.1038/bmt.2014.15. Epub 2014 Feb 17.</citation>
    <PMID>24535125</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C, et al. Successful engraftment of T-cell-depleted haploidentical &quot;three-loci&quot; incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994 Dec 1;84(11):3948-55.</citation>
    <PMID>7524753</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20;23(15):3447-54. Epub 2005 Mar 7.</citation>
    <PMID>15753458</PMID>
  </reference>
  <reference>
    <citation>Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997 May 15;89(10):3864-72.</citation>
    <PMID>9160695</PMID>
  </reference>
  <reference>
    <citation>Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M, Izutsu K, Hangaishi A, Tsujino S, Ogawa S, Motokura T, Chiba S, Hirai H. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation. 2005 May 27;79(10):1351-7.</citation>
    <PMID>15912103</PMID>
  </reference>
  <reference>
    <citation>Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, Jiang Q, Shi HX, Lu DP. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006 Aug;38(4):291-7. Erratum in: Bone Marrow Transplant. 2008 Aug;42(4):295. Dosage error in article text.</citation>
    <PMID>16883312</PMID>
  </reference>
  <reference>
    <citation>Cho BS, Yoon JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Kim HJ. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012 Oct;18(10):1552-63. doi: 10.1016/j.bbmt.2012.04.008. Epub 2012 Apr 16.</citation>
    <PMID>22516055</PMID>
  </reference>
  <reference>
    <citation>Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007 Feb 20;25(6):690-7. Epub 2007 Jan 16.</citation>
    <PMID>17228020</PMID>
  </reference>
  <reference>
    <citation>Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.</citation>
    <PMID>17869547</PMID>
  </reference>
  <reference>
    <citation>Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003 Mar 1;21(5):774-80. Epub 2003 Mar 1.</citation>
    <PMID>12610173</PMID>
  </reference>
  <reference>
    <citation>Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, Mattano LA Jr, Sather H, Devidas M, Freyer DR, Steinherz PG, Seibel NL. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009 Nov 1;27(31):5189-94. doi: 10.1200/JCO.2008.20.8959. Epub 2009 Oct 5.</citation>
    <PMID>19805689</PMID>
  </reference>
  <reference>
    <citation>Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009 Jun;146(1):76-85. doi: 10.1111/j.1365-2141.2009.07712.x. Epub 2009 May 4.</citation>
    <PMID>19438471</PMID>
  </reference>
  <reference>
    <citation>Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, Tedeschi A, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005 May 1;105(9):3434-41. Epub 2005 Jan 13.</citation>
    <PMID>15650057</PMID>
  </reference>
  <reference>
    <citation>Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008 Mar 1;111(5):2563-72. Epub 2007 Dec 21.</citation>
    <PMID>18156492</PMID>
  </reference>
  <reference>
    <citation>Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, Cherry AM, Higgins RR, Fielding AK, Foroni L, Paietta E, Tallman MS, Litzow MR, Wiernik PH, Rowe JM, Goldstone AH, Dewald GW; Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007 Apr 15;109(8):3189-97. Epub 2006 Dec 14.</citation>
    <PMID>17170120</PMID>
  </reference>
  <reference>
    <citation>Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J; Children's Cancer Group; Cancer and Leukemia Group B studies. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008 Sep 1;112(5):1646-54. doi: 10.1182/blood-2008-01-130237. Epub 2008 May 23.</citation>
    <PMID>18502832</PMID>
  </reference>
  <reference>
    <citation>Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18;113(25):6330-7. doi: 10.1182/blood-2008-04-151860. Epub 2008 Aug 14.</citation>
    <PMID>18703706</PMID>
  </reference>
  <reference>
    <citation>Chang H, Jiang A, Brandwein J. Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010 Jun;95(6):1040-2; author reply 1042. doi: 10.3324/haematol.2009.021089. Epub 2010 Jan 27.</citation>
    <PMID>20107157</PMID>
  </reference>
  <reference>
    <citation>Campana D, Leung W. Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol. 2013 Jul;162(2):147-61. doi: 10.1111/bjh.12358. Epub 2013 May 9. Review.</citation>
    <PMID>23654352</PMID>
  </reference>
  <reference>
    <citation>Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia. 2007 Apr;21(4):622-6. Epub 2007 Feb 15. Review.</citation>
    <PMID>17301806</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Dae-Young Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>alternative hematopoietic stem cell donor</keyword>
  <keyword>busulfan</keyword>
  <keyword>antithymocyte globulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

